Demirhan O. Demir, Department of Urology, Clinic of Ankara Training and Research Hospital, University of Medical Sciences, Ankara, Turkey
Omer G. Doluoglu, Department of Urology, Clinic of Ankara Training and Research Hospital, University of Medical Sciences, Ankara, Turkey
Ali K. Yildiz, Department of Urology, Clinic of Ankara Training and Research Hospital, University of Medical Sciences, Ankara, Turkey
Turgay Kacan, Department of Urology, Clinic of Ankara Training and Research Hospital, University of Medical Sciences, Ankara, Turkey
Veli M. Yazar, Department of Urology, Clinic of Ankara Training and Research Hospital, University of Medical Sciences, Ankara, Turkey
Arif Demirbas, Department of Urology, Clinic of Ankara Training and Research Hospital, University of Medical Sciences, Ankara, Turkey
Berat C. Ozgur, Department of Urology, Clinic of Ankara Training and Research Hospital, University of Medical Sciences, Ankara, Turkey


Objective: We aimed to investigate the significance of time to re-staging transurethral resection (re-TUR) on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer as a prospective randomized study. Methods: The patients were randomly separated into three groups according to Re-TUR timing. In Groups 1, 2, and 3, the time interval between initial and re-TUR was 14-28 days, 29-42 days, and 43-56 days, respectively. Cox regression analysis was used to assess the effect of time from initial TUR to re-TUR on oncological outcomes. Results: Twenty patients in Group 1 (14-28 days), 22 patients in Group 2 (29-42 days), and 29 patients in Group 3 (43-56 days) completed the study. Kaplan–Meier plots showed no differences in recurrence-free survival (RFS) and progression-free survival (PFS) rates between the three groups. Cox regression analysis demonstrated that only tumor number was found to be a prognostic factor on RFS rates. Conclusion: Our prospective study demonstrated that time laps from initial TUR to re-TUR did not significantly affect on RFS and PFS rates.



Keywords: Non-muscle invasive bladder cancer. Restaging transurethral resection. High grade. Oncological outcomes.